Home Hyperhomocysteinemia and thrombophilia
Article
Licensed
Unlicensed Requires Authentication

Hyperhomocysteinemia and thrombophilia

  • Mojca Božič-Mijovski EMAIL logo
Published/Copyright: November 25, 2010
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 48 Issue s1

Abstract

It is now widely accepted that hyperhomocysteinemia (HHC) is a risk factor for thrombophilia. HHC is the result of either impaired enzyme function or a deficiency of vitamin B (folate, B6, B12), or both, and can be treated with vitamin supplements. Measuring plasma total homocysteine (tHcy) is included in the routine thrombophilia panel in many laboratories, despite having a limited value to the clinician. Many methods are available for tHcy measurements. High-pressure liquid chromatography (HPLC) with fluorescence detection is a widely used method, but is being replaced by more convenient immuno- or enzyme assays. In this paper a general overview on homocysteine is given, with an emphasis on laboratory methods.

Clin Chem Lab Med 2010;48:S89–95.


Corresponding author: Mojca Božič-Mijovski, Department of Vascular Diseases, University Medical Centre, 1000 Ljubljana, Slovenia Phone: +386 1 522 8032, Fax: +386 1 522 8070

Received: 2010-6-3
Accepted: 2010-9-7
Published Online: 2010-11-25
Published in Print: 2010-12-01

©2010 by Walter de Gruyter Berlin New York

Downloaded on 25.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm.2010.365/html?lang=en
Scroll to top button